Krystal Biotech (NASDAQ:KRYS) Upgraded to Hold by Zacks Investment Research


Share on StockTwits

Zacks Investment Research upgraded shares of Krystal Biotech (NASDAQ:KRYS) from a sell rating to a hold rating in a research report released on Wednesday morning, Zacks.com reports.

According to Zacks, “Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. “

KRYS has been the subject of several other research reports. B. Riley reiterated a buy rating and set a $100.00 price target on shares of Krystal Biotech in a research report on Wednesday, November 11th. HC Wainwright lifted their price target on shares of Krystal Biotech from $68.00 to $84.00 and gave the stock a buy rating in a research report on Friday, January 8th. Finally, BidaskClub upgraded shares of Krystal Biotech from a hold rating to a buy rating in a research report on Wednesday, December 16th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $90.00.

Shares of NASDAQ:KRYS opened at $65.05 on Wednesday. Krystal Biotech has a one year low of $33.08 and a one year high of $70.07. The company has a 50 day moving average of $58.21 and a 200-day moving average of $47.59. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -43.95 and a beta of 1.20.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Saturday, November 14th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.02). On average, sell-side analysts anticipate that Krystal Biotech will post -1.78 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its stake in Krystal Biotech by 7.9% during the 3rd quarter. BlackRock Inc. now owns 1,196,920 shares of the company’s stock worth $51,527,000 after acquiring an additional 87,936 shares during the last quarter. Vanguard Group Inc. lifted its stake in Krystal Biotech by 13.6% in the second quarter. Vanguard Group Inc. now owns 724,653 shares of the company’s stock valued at $30,015,000 after buying an additional 86,605 shares in the last quarter. Point72 Asset Management L.P. lifted its stake in Krystal Biotech by 23.1% in the third quarter. Point72 Asset Management L.P. now owns 663,889 shares of the company’s stock valued at $28,580,000 after buying an additional 124,647 shares in the last quarter. Victory Capital Management Inc. lifted its stake in Krystal Biotech by 88.5% in the third quarter. Victory Capital Management Inc. now owns 524,144 shares of the company’s stock valued at $22,565,000 after buying an additional 246,047 shares in the last quarter. Finally, C WorldWide Group Holding A S lifted its stake in Krystal Biotech by 36.8% in the third quarter. C WorldWide Group Holding A S now owns 185,809 shares of the company’s stock valued at $7,999,000 after buying an additional 50,000 shares in the last quarter. 71.01% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a gene therapy company, develops and commercializes medicines for patients suffering from skin diseases in the United States. The company's lead product candidate is beremagene geperpavec (B-VEC), which has completed Phase I/II clinical study to treat dystrophic epidermolysis bullosa.

Featured Article: Neutral Rating

Get a free copy of the Zacks research report on Krystal Biotech (KRYS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.